Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific transaction rather than a financial performance report.
Material Changes
The filing details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary share ADRs on June 10, 2011, at a price of $41.57 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Points
- Transaction Date: June 10, 2011 (Notification date: June 13, 2011).
- Parties Involved: Dr. M M Slaoui (Director/PDMR) and Dr. K Slaoui (Connected Person).
- Instrument: 5 Ordinary share ADRs.
- Price: $41.57 per ADR.
- Context: Increase in notional allocation due to plan re-valuation.